These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17264335)

  • 1. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
    Weingart J; Grossman SA; Carson KA; Fisher JD; Delaney SM; Rosenblum ML; Olivi A; Judy K; Tatter SB; Dolan ME
    J Clin Oncol; 2007 Feb; 25(4):399-404. PubMed ID: 17264335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
    Schilsky RL; Dolan ME; Bertucci D; Ewesuedo RB; Vogelzang NJ; Mani S; Wilson LR; Ratain MJ
    Clin Cancer Res; 2000 Aug; 6(8):3025-31. PubMed ID: 10955780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
    Quinn JA; Desjardins A; Weingart J; Brem H; Dolan ME; Delaney SM; Vredenburgh J; Rich J; Friedman AH; Reardon DA; Sampson JH; Pegg AE; Moschel RC; Birch R; McLendon RE; Provenzale JM; Gururangan S; Dancey JE; Maxwell J; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
    J Clin Oncol; 2005 Oct; 23(28):7178-87. PubMed ID: 16192602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
    Quinn JA; Jiang SX; Carter J; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Threatt S; Friedman HS
    Clin Cancer Res; 2009 Feb; 15(3):1064-8. PubMed ID: 19188181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
    Friedman HS; Pluda J; Quinn JA; Ewesuedo RB; Long L; Friedman AH; Cokgor I; Colvin OM; Haglund MM; Ashley DM; Rich JN; Sampson J; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Stewart ES; Tourt-Uhlig S; Garcia-Turner AM; Herndon JE; Bigner DD; Dolan ME
    J Clin Oncol; 2000 Oct; 18(20):3522-8. PubMed ID: 11032594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
    Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
    Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
    Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
    Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
    Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
    J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
    Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
    Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
    Friedman HS; Kokkinakis DM; Pluda J; Friedman AH; Cokgor I; Haglund MM; Ashley DM; Rich J; Dolan ME; Pegg AE; Moschel RC; McLendon RE; Kerby T; Herndon JE; Bigner DD; Schold SC
    J Clin Oncol; 1998 Nov; 16(11):3570-5. PubMed ID: 9817277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
    Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD
    JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
    Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; Chan DV; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD
    Arch Dermatol; 2012 May; 148(5):613-20. PubMed ID: 22250189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
    Adams DM; Zhou T; Berg SL; Bernstein M; Neville K; Blaney SM;
    Pediatr Blood Cancer; 2008 Mar; 50(3):549-53. PubMed ID: 17941066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
    Dolan ME; Posner M; Karrison T; Radosta J; Steinberg G; Bertucci D; Vujasin L; Ratain MJ
    Clin Cancer Res; 2002 Aug; 8(8):2519-23. PubMed ID: 12171878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
    Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
    Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
    Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
    J Clin Oncol; 2009 Mar; 27(8):1262-7. PubMed ID: 19204199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
    Dolan ME; Roy SK; Fasanmade AA; Paras PR; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 May; 16(5):1803-10. PubMed ID: 9586894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.